-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NxQTD7m/bYz9qtWiMUKRzmiA6GuqkbNwcZrHAYfVV/Ka/eR0Cn+ITrINoZnUs1gI
 N98YRT0L7mmRXWZ4BNMBNg==

<SEC-DOCUMENT>0001297077-07-000023.txt : 20070614
<SEC-HEADER>0001297077-07-000023.hdr.sgml : 20070614
<ACCEPTANCE-DATETIME>20070614172549
ACCESSION NUMBER:		0001297077-07-000023
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070611
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070614
DATE AS OF CHANGE:		20070614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS BIOTECHNOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-EATING & DRINKING PLACES [5810]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		07920770

	BUSINESS ADDRESS:	
		STREET 1:		2200 WILSON BLVD
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201
		BUSINESS PHONE:		703-526-0400

	MAIL ADDRESS:	
		STREET 1:		2200 WILSON BLVD.
		STREET 2:		SUITE 102-316
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cbi8k_hidalgo-bod.htm
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>UNITED STATES</title>
</head>

<body >
<ul>
</ul>

<p>
<p align="center">
<b>UNITED STATES</b><br><b>SECURITIES AND EXCHANGE
COMMISSION</b><br><b>Washington, D.C. 20549</b><p align="center">
<b>FORM 8-K</b><p align="center">
<b>CURRENT REPORT</b><br><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</b><p align="center">
<font size="2">Date of Report (Date of earliest event
reported)</font><br><font size="2">June 11, 2007</font><p align="center">
<b>CHAMPIONS BIOTECHNOLOGY, INC</b>.<br><font size="2">(Exact name of registrant
as specified in its charter)</font></p align="center">
<div align="center" style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Delaware</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">0-17263</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">52-1401755</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(State of other jurisdiction</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Commission</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(IRS Employer</font></p align="center">
</td>
</tr>
<tr valign="top">
<td width="173.333290" colspan="1" rowspan="1" >
<p align="center">
<font size="2">of incorporation)</font></p align="center">
</td>
<td width="149.333296" colspan="1" rowspan="1" >
<p align="center">
<font size="2">File Number)</font></p align="center">
</td>
<td width="167.999958" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Identification No.)</font></p align="center">
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">2200 Wilson Blvd.</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Suite 102-316</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">Arlington, VA</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
&nbsp;22201	</td>
</tr>
<tr valign="top">
<td width="238.666607" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Address of principal executive
offices)</font></p align="center">
</td>
<td width="107.999973" colspan="1" rowspan="1" >
<p align="center">
<font size="2">(Zip Code)</font></p align="center">
</td>
</tr>
</table></div>
<p>
<p align="center">
<font size="2">Registrant&#8217;s telephone number, including area code: (703)
526-0400</font><p align="center">
<font size="2">(Former name or former address, if changed since last
report.)</font></p>
&nbsp;	<p>
<font size="2">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</font><p>
<font size="2">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</font><br><font size="2">[&nbsp;&nbsp;]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</font><br><font size="2">[&nbsp;&nbsp;] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b></b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
<!--<a name="_Toc147111976"></a>--><font size="2"><b>Item 3.02. Unregistered Sales of
Equity Securities</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May 15, 2007
Champions Biotechnology, Inc. granted Dr. Manuel Hidalgo 500,000 stock options
at $0.30 per share, the market price of those shares,  as incentive to joining
the Board of Directors  and to serve as Scientific Advisor. The options are to
vest over three years as follows: 166,665 shares upon the first and second
anniversaries of the grant date and 166, 670 shares upon the third anniversary
of the grant date. Champions Biotechnology issued the options and shares to Dr.
Hidalgo in reliance upon the exemption from registration provided by Section
4(2) of the Securities Act. </font><p>
<font size="2"><b>Item 5.03. Amendments to Article of Incorporation or Bylaws;
Change in Fiscal Year.</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June 11, 2007, Dr.
Manuel Hidalgo, after receiving all third party approvals, accepted the
appointment to the Board of Directors and agreed to serve as the Scientific
Advisor.  In that capacity, he will advise and assist Champions Biotechnology in
the development of novel Benzoylphenylurea (BPU) sulfur analog compounds and the
novel human cancer xenograft platform that Champions Biotechnology acquired
recently. In addition, Dr. Hidalgo will advise Champions Biotechnology on future
therapeutic drug candidates and technologies that Champions Biotechnology
intends to acquire. He will also assist Champions Biotechnology in the formation
of its Scientific Advisory Board. </font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the past five
years, Dr. Hidalgo has been an Associate Professor of Oncology at the Sidney
Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine.
He is also currently the Director of the Centro Integral Oncologia &#8220;Clara
Campal&#8221; in Madrid, Spain. Dr. Hidalgo is serving on the Scientific
Advisory Boards of private and public companies, including Systems Medicine, Tau
Therapeutics, Targeted Molecular Diagnostics and Monogram Biosciences. Dr.
Hidalgo is considered a leading researcher in the field of targeted therapies
for the treatment of cancer in patients with solid tumors. His research interest
focuses on the development of novel anticancer agents for patients with
gastrointestinal cancer by measuring target receptor and molecular anomalies, as
well as analyzing biological activity in the tumor and normal tissues of
patients treated with specific therapies. Dr. Hidalgo has published over 140
papers in prestigious cancer journals as well as numerous chapters in important
text books. He has received numerous awards including an AACR Young Investigator
Award, an NCI-EORTC fellowship and an ASCO Career Development Award. He has
served on the editorial board of the Journal of Clinical Oncology and Clinical
Cancer Research and is a Senior Editor for Molecular Cancer Therapeutics. Dr.
Hidalgo has chaired the AACR and ASCO Program Committee in developmental
therapeutics on numerous occasions and is frequently invited to speak at major
national and international meetings. He chairs the Pancreatic Cancer Research
Team, a nonprofit organization focused on clinical trials in pancreatic cancer
and is also a member of the NCI Developmental Therapeutics Study
Section.</font><p>
<font size="2"><b>Item 8.01. Other Events</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June 11, 2007, the
Registrant issued a press release, a copy of which is attached to this Current
Report on Form 8-K as Exhibit 99.1, in connection with the matter described
under Item 5.03 of this Current Report on Form 8-K. </font><p>
<!--<a name="OLE_LINK1"></a>--><!--<a name="_Toc147111982"></a>--><font size="2"><b>Item 9.01.
Financial Statements and Exhibits</b></font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Exhibits</font><p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press
release dated June 11, 2007</font></p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>2</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p align="center">
<font size="2"><b>SIGNATURES</b></font><p>
<font size="2">Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</font></p>
<div style="position:relative; left: 0"><table border=0 cellpadding=0 cellspacing =0 >
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
<p>
<font size="2">Date: June 14, 2007</font></p>
</td>
<td width="277.333264" colspan="2" rowspan="1" >
<p>
<font size="2">CHAMPIONS SPORTS, INC.</font></p>
</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="3" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="3" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="637.333174" colspan="3" rowspan="1" >
&nbsp;</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">By:</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2"><u>/s/&nbsp;&nbsp;James Martell</u></font></p>
</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James Martell</font></p>
</td>
</tr>
<tr valign="top">
<td width="359.999910" colspan="1" rowspan="1" >
&nbsp;</td>
<td width="23.999994" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;</font></p>
</td>
<td width="253.333270" colspan="1" rowspan="1" >
<p>
<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</font></p>
</td>
</tr>
</table></div>
<p>
</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>3</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>hidalgopressrelease.htm
<DESCRIPTION>PRESS RELEASE - HIDALGO BOD
<TEXT>
<html>
<head><meta content="text/html; charset=iso-8859-1">
<title>Champions Sports, Inc</title>
</head>

<body >
<ul>
</ul>

<p align="right">
Exhibit 99.1<p align="center">
<font face="Eras Demi ITC" size="5" color="#ff0000">CHAMPIONS  Biotechnology,
Inc.</font><br><font face="Eras Demi ITC">2200 Wilson Boulevard, Suite
102-316</font><br><font face="Eras Demi ITC">Arlington, VA 22201,
USA</font><br><font face="Eras Demi ITC">Tel:
703-526-0400</font><br><font face="Eras Demi ITC">Fax:
703-832-8311</font><p align="center">
<font size="4"><b>Dr. Manuel Hidalgo Appointed Director and Scientific Advisor
of Champions Biotechnology, Inc.</b></font><p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arlington, VA., June 11, 2007.
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a development stage
biotechnology company, announced the appointment of Dr. Manuel Hidalgo to serve
as a Director on the Company&#8217;s Board of Directors and as a Scientific
Advisor. In that capacity he will advise and assist the Company in the
development of novel Benzoylphenylurea (BPU) sulfur analog compounds and the
novel human cancer xenograft platform that the Company acquired recently. In
addition, Dr. Hidalgo will advise the Company on future therapeutic drug
candidates and technologies that the Company intends to acquire. He will also
assist the Company in the formation of its Scientific Advisory Board.  <p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Manuel Hidalgo, M.D., Ph.D., is
the Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer
Center, Johns Hopkins University School of Medicine and Director of the
<i>Centro Integral Oncologia</i> <i>&#8220;Clara Campal&#8221;</i> in Madrid,
Spain. He is considered a leading researcher in the field of targeted therapies
for the treatment of cancer in patients with solid tumors. His research interest
focuses on the development of novel anticancer agents for patients with
gastrointestinal cancer by measuring target receptor and molecular anomalies, as
well as analyzing biological activity in the tumor and normal tissues of
patients treated with specific therapies. Dr. Hidalgo&#8217;s laboratory has
been involved in the development of the Champions Biotechnology&#8217;s BPU
sulfur analog compounds, published recently in the <i>American Association for
Cancer Research Journal of Molecular Cancer Therapeutics, Vol. 6, Issue 5, May
2007, 1509-16.</i> <p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"The Company is very excited to have
such a recognized leader in the field agree to join its Board of Directors and
also become the Scientific Advisor.&#8221; said James Martell, Chairman,
President and CEO of Champions Biotechnology. &#8220;Dr. Hidalgo&#8217;s
combination of clinical and research expertise and contacts in industry and
government will be invaluable to the Company as we begin our growth as a
biotechnology company.&#8221; <p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Hidalgo has published over 140
papers in prestigious cancer journals as well as numerous chapters in important
text books.  He has received numerous awards including an AACR Young
Investigator Award, an NCI-EORTC fellowship and an ASCO Career Development
Award. He has served on the editorial board of the Journal of Clinical Oncology
and Clinical Cancer Research and is a Senior Editor for Molecular Cancer
Therapeutics. Dr. Hidalgo has chaired the AACR and ASCO Program Committee in
developmental therapeutics on numerous occasions and is frequently invited to
speak at major national and international meetings.  He chairs the Pancreatic
Cancer Research Team, a nonprofit organization focused on clinical trials in
pancreatic cancer and is also a member of the NCI Developmental Therapeutics
Study Section.   </p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>1</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>About Champions Biotechnology, Inc.
</i><p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Champions Biotechnology is a
biotechnology company that is engaged in the acquisition and early stage
development of a portfolio of new therapeutic drug candidates and also the
acquisition and development of novel technologies that Champions Biotechnology
hopes will improve methods of and approaches to disease treatment.  This is
being accomplished by drawing upon the established expertise, knowledge and
insight of experts, including two of Champions Biotechnology&#8217;s
shareholders, Drs. David Sidransky and Manuel Hidalgo, who have wide-ranging
contacts in the pharmaceutical industry, academia and government.<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Champions Biotechnology plans to
develop a portfolio of new therapeutic drug candidates through pre-clinical
trials and possibly early phase ("first in man") clinical trials.  If
therapeutic drug candidates reach this early stage of development, Champions
Biotechnology intends to partner with, sell or license them to pharmaceutical
and/or biotechnology companies, as appropriate. Management believes this
strategy will enable Champions Biotechnology to leverage the competencies of
these partners or licensees to maximize Champions Biotechnology&#8217;s return
on investment in a relatively short time frame. Champions Biotechnology believes
that this model is unlike that of typical new biotechnology companies that look
to bring the process of drug development through all phases of discovery,
development, regulatory approvals, and marketing, which requires a very large
financial commitment and a long time, typically more than a decade, to
realize.<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2007, Champions
Biotechnology acquired the patent rights to two novel Benzoylphenylurea (BPU)
sulfur analog compounds that have shown promising potent activity against in
vitro and in vivo models of prostate and pancreatic cancer. <p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2007, Champions Biotechnology
acquired Biomerk Inc. a company focused on generating a novel preclinical
platform of human cancer tumor immune-deficient mice xenografts (Biomerk
Tumorgrafts&#8482;).  Biomerk Tumorgrafts&#8482;, unlike standard cell line
derived xenografts, are implanted directly from primary human cancer tumors and
never passaged in cell tissue culture. Champions Biotechnology believes that
these xenografts more closely reflect human cancer biology and are more
predictive of clinical outcome. Champions Biotechnology has several patent
applications relating to xenograft models used for identifying potentially
active chemotherapeutic agents. Champions Biotechnology believes that
pharmaceutical companies, as part of their drug discovery and post marketing
efforts, are more receptive to utilizing services that are more predictive and
that might provide for a faster and less expensive path for their drug approval.
These services will allow for their screening of Biomerk Tumorgrafts&#8482; to
evaluate tumor sensitivity/resistance to various single and combination standard
and novel chemotherapy agents. </p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>2</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This press release contains
"forward-looking statements" (within the meaning of the Private Securities
Litigation Act of 1995) that inherently involve risk and uncertainties.
Champions Biotechnology generally uses words such as "believe," "may," "could,"
"will," "intend," "expect," "anticipate," "plan," and similar expressions to
identify forward-looking statements. One should not place undue reliance on
these forward-looking statements. Champions Biotechnology&#8217;s actual results
could differ materially from those anticipated in the forward-looking statements
for many unforeseen factors, which may include, but are not limited to, changes
in general economic conditions, the ongoing threat of terrorism, ability to have
access to financing sources on reasonable terms and other risks that are
described in this document. Although Champions Biotechnology believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology&#8217;s future results, levels of activity, performance
or achievements may not meet these expectations. Champions Biotechnology does
not intend to update any of the forward-looking statements after the date of
this press release to conform these statements to actual results or to changes
in Champions Biotechnology&#8217;s expectations, except as required by law. </p>
&nbsp;	<p>
Contact: James Martell (703) - 526-0400</p align="center">
<div align="center" color="#000080" style="position:relative; left: -5"><b>3</b><hr size="3" color="#999999" STYLE="page-break-after: always"> &nbsp; </div><p>
</p>


</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
